Stockscreener 앱 받기
5.62
5.05%
0.27
시간 외 거래:
5.62
Alumis Inc 주식(ALMS)의 최신 뉴스
Alumis Inc. Reports Q1 2025 Financial Results and Strategic Progress - TipRanks
Oppenheimer Trims Price Target on Alumis to $25 From $26, Keeps Outperform Rating - marketscreener.com
Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements - The Manila Times
Alumis Inc. Reports First Quarter 2025 Financial Results - TradingView
Earnings Flash (ALMS) ALUMIS INC. Reports Q1 Revenue $17.4M - marketscreener.com
How a Peninsula biotech's merger drama overcame several investor headaches - The Business Journals
ACELYRIN shareholders approve Alumis merger deal By Investing.com - Investing.com India
Alumis wins shareholder nod for ACELYRIN merger By Investing.com - Investing.com India
Alumis, Acelyrin Shareholders Approve Merger Deal - marketscreener.com
ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases - The Manila Times
Alumis Inc. Stockholders Approve Merger with ACELYRIN, INC. - Nasdaq
Alumis wins shareholder nod for ACELYRIN merger - Investing.com Australia
Alumis Stockholders Approve Merger With Acelyrin - marketscreener.com
Acelyrin (SLRN) Stockholders Approve Merger with Alumis (ALMS) - StreetInsider
ACELYRIN-Alumis Merger Gets Green Light: New Powerhouse in Immune Disease Treatment Emerges - Stock Titan
Barclays PLC Has $193,000 Stock Holdings in Alumis Inc. (NASDAQ:ALMS) - Defense World
Mariner LLC Buys Shares of 18,122 Alumis Inc. (NASDAQ:ALMS) - Defense World
(ALMS) On The My Stocks Page - news.stocktradersdaily.com
Hedge Fund and Insider Trading News: Chris Rokos, Bill Ackman, Ken Griffin, Mario Gabelli, Eisler Capital, Coatue Management, Waratah Capital Advisors, Brevan Howard, Caxton Associates, Alumis Inc (ALMS), Microsoft Corp (MSFT), and More - Insider Monkey
Tuesday’s Top Insider Moves: Alumis Buys Surge, PennyMac Director Sells By Investing.com - Investing.com South Africa
Tuesday’s Top Insider Moves: Alumis Buys Surge, PennyMac Director Sells - Investing.com
Alumis Inc. sees $202,300 stock purchase by Foresite Capital - Investing.com India
Alumis director James Tananbaum acquires $202,300 in stock By Investing.com - Investing.com Canada
Alumis director James Tananbaum acquires $202,300 in stock - Investing.com Australia
Alumis Inc. sees $202,300 in stock purchases by Foresite Labs - Investing.com
Alumis director Srinivas Akkaraju buys shares worth $1.48 million By Investing.com - Investing.com Nigeria
Alumis director Srinivas Akkaraju buys shares worth $1.48 million - Investing.com Australia
ACELYRIN Encourages Stockholders to Support Merger with Alumis Inc. Following ISS Recommendation - Nasdaq
Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote 'FOR” the Proposed Transaction with Alumis - The Manila Times
Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the ... - Eagle-Tribune
Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis - Yahoo Finance
Alumis Inc. (NASDAQ:ALMS) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Acelyrin urges stockholders to vote for proposed merger with Alumis - Yahoo Finance
ACELYRIN urges stockholders to approve Alumis merger By Investing.com - Investing.com India
ACELYRIN urges stockholders to approve Alumis merger - Investing.com
ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis - The Manila Times
ACELYRIN, Inc. Urges Stockholders to Vote in Favor of Proposed Merger with Alumis Inc. Ahead of May 13, 2025 Meeting - Nasdaq
ACELYRIN Board Makes Final Push for Alumis Merger: 48% Ownership Deal at Stake in Critical May Vote - Stock Titan
Investor pressures Acelyrin to exit Alumis merger and liquidate, slams ‘inexplicable’ process - Fierce Biotech
Acelyrin gains as Trium Capital rebuffs M&A deal with Alumis - MSN
Acelyrin (SLRN) Faces Shareholder Opposition to Alumis Merger - GuruFocus
Acelyrin should liquidate instead of merging with Alumis, investor says - BioPharma Dive
Acelyrin stock gains as Trium rebuffs M&A deal (SLRN:NASDAQ) - Seeking Alpha
Alumis stock price target cut to $14 by H.C. Wainwright - Investing.com Australia
When (ALMS) Moves Investors should Listen - news.stocktradersdaily.com
Danaher expects about $350M in tariff costs; Alumis, Acelyrin adjust deal terms - Endpoints News
Charles Schwab To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Revised merger terms boost ACELYRIN stake in Alumis deal By Investing.com - Investing.com South Africa
1.54%
7.58%
자본화:
|
볼륨(24시간):